Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies

ACTIVE_NOT_RECRUITING

New York Presbyterian / Weill Cornell Medical Center, New York

NOT_YET_RECRUITING

Northwell Health, New Hyde Park

RECRUITING

Thomas Jefferson University, Philadelphia

RECRUITING

University of Maryland Medical Center, Baltimore

RECRUITING

University of California San Francisco (UCSF) Medical Center-Mission Bay, San Francisco

ACTIVE_NOT_RECRUITING

Carolina BioOncology Institute, Huntersville

RECRUITING

Winship Cancer Institute at Emory University, Atlanta

WITHDRAWN

Boca Raton Clinical Research (BRCR), Boca Raton

RECRUITING

University of Alabama at Birmingham, Birmingham

ACTIVE_NOT_RECRUITING

Sarah Cannon Research Institute, Nashville

RECRUITING

The Ohio State University Wexner Medical Center The James Cancer Hospital and Solove Research Institute, Columbus

SUSPENDED

UC Health - University of Cincinnati Medical Center, Cincinnati

RECRUITING

Karmanos Cancer Institute, Detroit

RECRUITING

University of Iowa Hospitals, Iowa City

RECRUITING

University of Wisconsin, Madison

RECRUITING

Washington University, St Louis

SUSPENDED

University of Nebraska Medical Center, Omaha

RECRUITING

MD Anderson Cancer Center, Houston

RECRUITING

University of Arizona College of Medicine-Tucson, Tucson

RECRUITING

UCLA Health Westwood Cancer Care, Los Angeles

RECRUITING

University of California Irvine (UCI) Medical Center, Orange

RECRUITING

University of California at San Francisio, San Francisco

RECRUITING

Massachusetts General Hospital, Boston

RECRUITING

University of Texas Southwestern Medical Center Harold C. Simmons Comprehensive Cancer Center, Dallas